Doximity, Inc.
NYSE:DOCSMedical - Healthcare Information Services
-$0.09 today
- Market cap
- $5.47B
- Beta
- 1.29
- P/E (TTM)
- 19.2
- EPS (TTM)
- $1.06
Volume 2.27M
Average 3.89M
DOCS Income Before Tax
Profit after all operating and non-operating items but before income tax.
Doximity, Inc.NYSE: DOCS
Income Before Tax · Q2 FY2027 · quarter ended Sep 2026
Income before tax declines year over year
Q2 FY2027 income before tax of $50.33M fell 31.0% year over year, behind the -28.6% change in trailing-twelve-month income before tax. Sequentially, it rose 24.7% from the prior quarter. Over 3 fiscal years it compounded at +23.4% a year.
Context
- Income before tax amounted to 38.8% of revenue in FY2026, down 7.4 pp from a year earlier.
- Income before tax increased in 2 of the last 3 fiscal years.
What to watch
Whether quarterly growth recovers from -31.0% toward the trailing-twelve-month pace of -28.6%.
Sources:Income StatementText generated from reported figures; not investment advice.
Income Before Tax history
USD · from the income statement
- Latest · FY2026
- 250.01M USD
- Year-over-year change
- -5.1%
- 4-year CAGR
- +21.7%
| Period | Period end | Income Before Tax | YoY change |
|---|---|---|---|
| FY2026 | 2026-03-31 | 250.01M | -5.1% |
| FY2025 | 2025-03-31 | 263.57M | +42.3% |
| FY2024 | 2024-03-31 | 185.2M | +39.1% |
| FY2023 | 2023-03-31 | 133.16M | +16.8% |
| FY2022 | 2022-03-31 | 114.01M | — |
Income Before Tax vs competitors
How DOCS compares with its peers on the latest reported figures
- DOCS's LTM Sep 2026 income before tax of $203.61M is the 7th highest of the 10 companies compared; the peer median is $308.71M.
- Its year-over-year change of -28.6% is the 9th highest of 10, against a peer median of +19.4%.
- Income before tax amounts to 30.8% of revenue for DOCS, versus a peer median of 12.8%.
| Company | Period | LTM | YoY | 3-year CAGR | % of revenue |
|---|---|---|---|---|---|
| LTM Jun 2026 | $1.7B | +428.3% | +0.4% | 20.4% | |
| LTM Jun 2026 | $1.03B | +19.4% | +28.3% | 16.6% | |
| LTM Jul 2026 | $462.4M | -25.2% | +6.0% | 10.9% | |
| LTM Jun 2026 | $417.71M | -48.9% | -23.5% | 5.1% | |
| LTM Jul 2026 | $308.71M | +66.7% | — | 22.7% | |
| LTM Jul 2026 | $260.77M | -17.5% | -25.6% | 9.0% | |
| LTM Sep 2026 | $203.61M | -28.6% | +23.4% | 30.8% | |
| LTM Sep 2026 | -$192.64M | +22.8% | — | 12.8% | |
| LTM Sep 2026 | -$485.9M | -22.2% | — | 38.0% | |
| LTM Jun 2026 | -$662.2M | +82.3% | — | 4.5% | |
| Peer median (excluding DOCS) | $308.71M | +19.4% | +0.4% | 12.8% | |
Competitors are the stored peer set for DOCS. Fiscal calendars differ, so each company's latest period is shown. Text is generated from reported figures; not investment advice.
Income Statement
Metric | FY2022 Mar 2022 | FY2023 Mar 2023 | FY2024 Mar 2024 | FY2025 Mar 2025 | FY2026 Mar 2026 |
|---|---|---|---|---|---|
| Revenue | 343.55M | 419.05M | 475.42M | 570.4M | 644.86M |
| Cost of Revenue | 39.79M | 53.49M | 50.67M | 55.87M | 70.33M |
| Gross Profit | 303.76M | 365.56M | 424.75M | 514.53M | 574.54M |
| Gross Margin | 88.4% | 87.2% | 89.3% | 90.2% | 89.1% |
| Research & Development | 62.35M | 80.19M | 81.98M | 93.04M | 130.7M |
| Selling, General & Admin | 127.88M | 160.27M | 170.96M | 191.38M | 228.92M |
| Operating Expenses | 190.23M | 240.45M | 260.88M | 286.73M | 359.62M |
| Depreciation & Amortization | 5.04M | 10.28M | 10.27M | 10.66M | 14.38M |
| EBITDA | 119.05M | 143.44M | 182.08M | 240.76M | 264.39M |
| EBITDA Margin | 34.7% | 34.2% | 38.3% | 42.2% | 41.0% |
| Operating Income | 113.54M | 125.11M | 163.88M | 227.8M | 214.92M |
| Operating Margin | 33.0% | 29.9% | 34.5% | 39.9% | 33.3% |
| Interest Income | 2.15M | 9.29M | 21.66M | 35.85M | 35.7M |
| Interest Expense | 0 | 0 | 0 | 0 | 0 |
| Other Income / Expenses | 469K | 8.05M | 21.32M | 35.77M | 35.09M |
| Income Before Tax | 114.01M | 133.16M | 185.2M | 263.57M | 250.01M |
| Pre-Tax Margin | 33.2% | 31.8% | 39.0% | 46.2% | 38.8% |
| Income Tax Expense | (40.78M) | 20.34M | 37.62M | 40.39M | 53.95M |
| Net Income | 154.78M | 112.82M | 147.58M | 223.19M | 196.05M |
| Net Margin | 45.1% | 26.9% | 31.0% | 39.1% | 30.4% |
| EPS (Basic) | 0.81 | 0.58 | 0.78 | 1.19 | 1.05 |
| EPS (Diluted) | 0.70 | 0.53 | 0.72 | 1.11 | 0.98 |
| Weighted Avg Shares | 163.48M | 193.18M | 190.17M | 186.84M | 187.01M |
| Weighted Avg Shares (Diluted) | 191.02M | 213.43M | 205.73M | 201.21M | 199.05M |
Doximity, Inc.
NYSE:DOCS
Intrinsic Alpha fair value
Locked
Current Price
$30.67
Unlock the intrinsic value to see where the current price sits on the valuation runway.
Valuation runway
LockedGet the intrinsic value and margin of safety with a free account.
Continue the stock analysis
Jump to another research area for this company.